East-West Hepatocellular Carcinoma Study Group
EAST-WEST HEPATOCELLULAR CARCINOMA STUDY GROUP
1 other identifier
observational
N/A
0 countries
N/A
Brief Summary
The current treatment guidelines of hepatocellular carcinoma (HCC) of the American and European Associations for the Study of Liver Disease are based on the Barcelona-Clinic-Liver-Cancer classification (BCLC), which does not recommend surgery in patients with large, multinodular and macrovascular invasive disease. The aim of this study was to investigate the role of hepatic resection in a large retrospective multicentric cohort of patients resected for HCC regardless of the BCLC indications.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 8, 2010
CompletedFirst Posted
Study publicly available on registry
November 9, 2010
CompletedNovember 9, 2010
December 1, 2009
November 8, 2010
November 8, 2010
Conditions
Outcome Measures
Primary Outcomes (1)
Overall survival of resected patients for HCC
The primary endpoint of the study was the overall survival of patients resected for HCC in any stage of the BCLC classification.
Secondary Outcomes (1)
Disease-free survival of resected patients for HCC
Eligibility Criteria
Patients affected by HCC
You may qualify if:
- clinical diagnosis of hepatocellular carcinoma
- candidate to liver resection as a curative treatment
You may not qualify if:
- uncertain diagnosis of hepatocellular carcinoma
- uncertain follow-up data
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
November 8, 2010
First Posted
November 9, 2010
Last Updated
November 9, 2010
Record last verified: 2009-12